Targeting At Risk Relatives Of Glaucoma Patients For Early Diagnosis And Treatment (TARRGET)
Funder
National Health and Medical Research Council
Funding Amount
$595,375.00
Summary
Glaucoma is the second leading cause of blindness in Australia but early detection and treatment can prevent blindness. We will recruit patients with advanced glaucoma from an Australia wide registry and refer their close relatives to have an eye exam and genetic testing to see if they are at risk of glaucoma. We will evaluate how a coordinator can improve the uptake of this screening program referring people to local eye care providers and in rural WA providing screening in 16 remote locations.
Saving The Optic Nerve : Manipulating The Shp2-Caveolin Axis
Funder
National Health and Medical Research Council
Funding Amount
$546,395.00
Summary
Glaucoma is a leading cause of blindness with many patients experiencing progressive vision loss despite treatment. We propose to use gene therapy techniques to manipulate the signalling pathway of Brain Derived Neurotrophic Factor and its receptor, along with biochemical and functional approaches to understand the mechanisms of glaucoma mediated eye damage and to develop new therapeutic strategies.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Harnessing Anticalin Technology As A Multi-targeted Treament Approach For Vision Loss
Funder
National Health and Medical Research Council
Funding Amount
$627,273.00
Summary
Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.
Young Adult Myopia: Genetic And Environmental Associations
Funder
National Health and Medical Research Council
Funding Amount
$809,271.00
Summary
Myopia affects 80% of school leavers in the cities of East Asia, 45% of Asian Australian school leavers and is probably on the rise in European Australian adolescents. Increased levels of education and lack of time outdoors are known to increase the risk of myopia. We will examine 2,000 young adults to find the genes that interact with these risk factors. In addition to confirming when these risk factors are most important, identifying molecular pathways opens the avenue of new treatments.
Seeing Clearly: Examining The Consequences Of Glaucoma For The Human Brain
Funder
National Health and Medical Research Council
Funding Amount
$439,694.00
Summary
Glaucoma is a major cause of blindness. Many people are unaware of the resulting blind region (scotoma) and fail to get an eye test, allowing the disease to progress. This project aims to see how the brain ‘fills in’ the scotoma, and the effect of different scotoma types, using vision tests, brain imaging, and behavioural methods. The results will tell us whether the region around a scotoma helps or hinders the person's remaining vision, which is critical for activities such as driving.